Cognitive and behavioural but not motor impairment increases brain age in amyotrophic lateral sclerosis

Andreas Hermann,1,2,3 Gaël Nils Tarakdjian,1,3 Anna Gesine Marie Temp,1,3 Elisabeth Kasper,4 Judith Machts,5,6,7 Jörn Kaufmann,8 Stefan Vielhaber,7,8 Johannes Prudlo,4 James H. Cole,9,10 Stefan Teipel3,11 and Martin Dyrba3

Age is the most important single risk factor of sporadic amyotrophic lateral sclerosis. Neuroimaging together with machine-learning algorithms allows estimating individuals’ brain age. Deviations from normal brain-ageing trajectories (so called predicted brain age difference) were reported for a number of neuropsychiatric disorders. While all of them showed increased predicted brain-age difference, there is surprisingly few data yet on it in motor neurodegenerative diseases. In this observational study, we made use of previously trained algorithms of 3377 healthy individuals and derived predicted brain age differences from volumetric MRI scans of 112 amyotrophic lateral sclerosis patients and 70 healthy controls. We correlated predicted brain age difference scores with voxel-based morphometry data and multiple different motoric disease characteristics as well as cognitive/behavioural changes categorized according to Strong and Rascovsky. Against our primary hypothesis, there was no higher predicted brain-age difference in the amyotrophic lateral sclerosis patients as a group. None of the motoric phenotypes/characteristics influenced predicted brain-age difference. However, cognitive/behavioural impairment led to significantly increased predicted brain-age difference, while slowly progressive as well as cognitive/behavioural normal amyotrophic lateral sclerosis patients had even younger brain ages than healthy controls. Of note, the cognitive/behavioural normal amyotrophic lateral sclerosis patients were identified to have increased cerebellar brain volume as potential resilience factor. Younger brain age was associated with longer survival. Our results raise the question whether younger brain age in amyotrophic lateral sclerosis with only motor impairment provides a cerebral reserve against cognitive and/or behavioural impairment and faster disease progression. This new conclusion needs to be tested in subsequent samples. In addition, it will be interesting to test whether a potential effect of cerebral reserve is specific for amyotrophic lateral sclerosis or can also be found in other neurodegenerative diseases with primary motor impairment.

1 Translational Neurodegeneration Section “Albrecht Kossel”, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany
2 Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany
3 Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Rostock/Greifswald, 18147 Rostock, Germany
4 Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany
5 Institute for Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany
6 Center for Behavioral Brain Sciences CBBS, 39104 Magdeburg, Germany
7 Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Magdeburg, 39120 Magdeburg, Germany
8 Department of Neurology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany
9 Centre for Medical Image Computing, Department of Computer Science, UCL, London, UK
10 Dementia Research Centre, Queen Square Institute of Neurology, UCL, London, UK
11 Department of Psychosomatic Medicine, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany

Received March 22, 2022. Revised July 01, 2022. Accepted September 21, 2022. Advance access publication September 22, 2022
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease. It is characterized by upper and lower motor neuron demise, leading to progressive paralysis and death within 1–5 years after symptom onset. On a group level, patients with ALS exhibit central nervous system involvement beyond the upper motor neuron system, including for example the frontotemporal lobes, hypothalamus and corpus callosum. Several factors may modify risk and speed of disease progression, including the initial disease manifestation (bulbar versus spinal) and the extend of frontotemporal impairment. Cognitive and behavioural impairment accompany motor decline in over half of the patients with ALS over the course of the disease. The most common cognitive deficits in ALS concern executive functions, especially verbal fluency. The revised consensus criteria of frontotemporal dysfunction in ALS by Strong et al. and by Rascovsky et al. in the case of frontotemporal dementia (FTD) patients with ALS characterize patients according to their cognitive deficits, extent of behavioural impairment and presence or absence of FTD. Notably, cognitive and behavioural impairments predict shorter survival time.

The single most relevant risk factor for sporadic ALS is age, with the highest prevalence of disease in patients over 60 years of age. This points towards an important role of
the ageing process itself. Normal ageing is a process of gradual accumulation of pathologies associated with cognitive and physical decline, which also affects brain volume and nerve cell loss.\textsuperscript{11,12} Thus, ALS might be considered as an increased ageing process of specific brain systems.

Neuroimaging data combined with machine-learning techniques can be used to predict the age of a healthy individual’s brain and allow measuring a potential deviance of an individual’s predicted brain age from chronologic age, termed ‘the predicted brain-age difference’ (PAD).\textsuperscript{13} This approach has been successfully applied not only in both early brain development and ageing in the healthy elderly (for a review see Franke and Gaser\textsuperscript{14}), but also in a number of disease conditions, including Alzheimer’s disease, schizophrenia, major depression, multiple sclerosis\textsuperscript{15} and epilepsy (for systematic review see Cole \textit{et al.}\textsuperscript{13} and Wrigglesworth \textit{et al.}\textsuperscript{16}). All disease conditions exhibited a remarkably increased PAD score, indicating that brain atrophy exceeded normal brain ageing. This was also true when investigating effects of known cardiovascular risk factors on brain ageing.\textsuperscript{17} In addition, increased PAD scores correlated well with increased mortality or decreased survival in a range of different conditions.\textsuperscript{15,18}

To date, there are only few reports on classical ‘motor’ neurodegenerative disorders, such as Parkinson’s disease and none on ALS. Hence, we chose ALS as a paradigmatic motor neurodegenerative disorder, since it has the advantage of clear definitions of motoric and cognitive/behavioural impairment. We hypothesized that patients with ALS would show increased brain age compared with healthy controls (HCs), and that this ageing process would be more pronounced in the presence of additional cognitive and/or behaviour impairment.

Materials and methods

Design

This two-centre prospective, observational cross-sectional study was conducted between April 2011 and August 2013. Local ethics committees of both universities approved the study (Rostock: A 2011 56; Magdeburg: 75/11) and all subjects gave written informed consent prior to their inclusion.

General methods used in this study have been already published\textsuperscript{19} and respective details are reported in the supplementary material. Specific methods relevant to the estimation of brain-age algorithm are described here.

Participants

We recruited 182 German participants in Rostock and Magdeburg, Germany. Persons with a history of brain injury, epilepsy or psychiatric illness were excluded. Control participants were screened for cognitive impairment using the Montreal cognitive assessment (MoCA) with a cut off of ≤26/30. Seventy HCs and 112 patients diagnosed with ALS according to Swinnen and Robberecht\textsuperscript{20} were included (Supplementary Fig. 1). These cases were characterized into ALS without cognitive/behavioural impairments (ALScn), ALS with cognitive impairment (ALSci), ALS with behaviour impairment (ALSbi), ALS with cognitive and behavioural impairments (ALSbc) and ALS with FTD (ALS-FTD) following the Strong and Rascovsky criteria.\textsuperscript{8,9} Different motoric phenotypes of ALS were classified as classical ALS, upper/lower motor neuron predominant (UMN/LMN) ALS, flail arm, flail leg and progressive muscular atrophy (PMA). None of the patient presented with pure primary lateral sclerosis (PLS). Demographic details are summarized in Table 1.

Clinical and neuropsychologic measures

Clinical and neuropsychologic measures were reported previously\textsuperscript{19} and thus reported in the Supplementary material. Examinations were done at the respective recruitment side.

MRI acquisition and processing

MRI scanning was performed with two 3 T Siemens Magnetom VERIO scanners (Erlangen, Germany) using a 32-channel head coil; one single scanner at each site (Rostock and Magdeburg, Germany). The anatomical T1-weighted images were segmented into grey matter, white matter and cerebrospinal fluid partitions using the SPM12 toolbox in Matlab 2019a. Then, the Diffomorphic Anatomical Registration Through Exponentiated Lie (DARTEL) algebra algorithm\textsuperscript{21} was used in combination with a custom brainAgeR brain template to normalize the T1-weighted images to the Montreal Neurological Institute (MNI) reference coordinate system. The estimated deformation fields were subsequently applied to the grey-matter segments to bring them in MNI space as well, followed by modulation to preserve the total amount of grey matter and smoothing with an 8 mm Gaussian kernel for the voxel-based morphometry (VBM) analysis.

Brain-age model and PAD

We estimated brain age in R, using the package ‘brainAgeR’, available at https://github.com/james-cole/brainAgeR. This algorithm was trained on $n = 3377$ healthy individuals and validated on 837 people. To predict brain age, we followed an automated pipeline starting with T1-weighted image segmentation and normalization using SPM12 with smoothing with a 4 mm Gaussian kernel to match with the training sample. Then, the spatially normalized grey- and white-matter segments as well as cerebrospinal fluid segments were loaded into R. They were masked to exclude voxels with $<30\%$ probability for cerebrospinal fluid, white matter or grey matter, respectively. Subsequently, these segments were vectorized to apply a principal component transformation. The transformed data were then entered in the pretrained Gaussian progress regression model to obtain the predicted
Table 1 Demographic Background of the Participants

| HC (N = 70) | ALS-FTD (N = 20) | ALS-sci (N = 29) | ALS-Sci (N = 5) | ALS-bi (N = 8) | ALS between all |
|------------|------------------|------------------|-----------------|---------------|----------------|
|             |                  |                  |                 |               | BF10            |
| N           | 6,000            | 6,000            | 6,000           | 6,000         | 6,000          |
| Sex (f/m; %) | 40/60 95%       | 36/64 95%       | 44/56 95%      | 50/50 95%    | 38/62 95%      |
| Age at examination (years) | 61.00 (10.67) | 59.94 (9.74) | 62.18 (11.62)   | 65.67 (14.62) | 61.21 (10.38)  |
| Education (years) | 13.36 (1.62)    | 13.48 (2.64)   | 11.86 (1.57)    | 13.83 (1.99)  | 11.60 (1.52)   |
| MoCA | 27.50 (1.29)    | 25.90 (2.45)    | 23.66 (1.59)    | 26.33 (3.94)  | 21.00 (3.94)   |
| Disease duration until TP1 (months) | 29.19 (38.76)  | 31.66 (35.14)  | 32.00 (30.21)   | 14.60 (11.55) | 19.13 (5.49)   |
| Total disease duration (months) | 63.59 (53.64)  | 42.81 (33.80)  | 43.89 (29.02)   | 30.50 (32.03) | 31.75 (6.99)   |
| Age at onset (years) | 57.25 (10.07)   | 58.35 (12.36)  | 54.25 (13.23)   | 63.78 (14.74) | 59.44 (10.36)  |
| EL Escorial criteria at test time (possible/probable/definitive/unknown; %) | 38/20/14/28  | 38/20/14/28  | 39/20/14/28    | 38/20/14/28  | 38/20/14/28  |
| Onset site (bulbar/spinal/no data; %) | 31/51.7/17.2 | 37.9/44.8/17.2 | 50/50/0         | 40/40/20     | 75/25/0        |
| ALS-FRSR (as close as possible to test time) | 39.00 (5.93)   | 38.07 (6.96)   | 34.82 (4.98)    | 36.80 (5.54)  | 41.57 (3.87)   |
| Δ ALS-FRSR (as close as possible to test time) | 0.65 (0.73)    | 1.40 (1.82)    | 1.12 (1.20)     | 0.91 (1.17)   | 0.99 (0.95)    |
| Δ ALS-FRSR (at diagnosis) | 0.49 (0.40)    | 0.57 (0.40)    | 0.89 (0.40)     | 0.99 (0.40)   | 0.46 (0.40)    |

Matching took place between HC and patients with ALS as a whole. Sex, age and education were matched successfully: independent Student’s t -tests supported the absence of differences in age and education, and a χ2 -test supported the absence of differences in sex distribution. Depicted are mean and SD if not mentioned differentially. aBF10 > 30 constitutes ‘very strong’ evidence for H1, BF10 > 10 constitutes ‘strong’ evidence for H1 and BF10 > 3 constitutes ‘moderate’ support for H1.

Brain age. Finally, the predicted age was subtracted from the chronologic age to calculate the PAD. While a positive PAD indicates an older appearing brain, a negative score suggests a younger appearing brain.

### Voxel-based analysis of group differences

Complementarily, we performed a whole-brain VBM analysis for which the normalized and smoothed grey-matter maps were analysed using Statistical Parametric Mapping (SPM12; [http://www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm)). All voxel-based analyses were controlled for total intracranial volume, chronologic age, sex and site, as these were potential nuisance variables. The statistical threshold for the analyses was set to an uncorrected $P < 0.001$ and only clusters with at least 50 voxels extent were retained in the results.

### Statistical analysis

As classical null hypothesis significance testing only enables us to reject the null hypothesis that there are no effects of clinical presentation on PAD, we opted for *Bayes factor hypothesis testing* (BFHT) using an analysis of covariance (ANCOVA). This Bayesian approach allows for the estimation of the likelihood of such effects given the observed data and, hence, more directly infer and compare the actual effects. Specifically, we compared the effects of Strong profile, progressor type, phenotype, onset type, disease duration until MRI scanning and age at disease onset, while controlling for age at MRI, sex and recruitment location by adding them to the null model. We conducted one multi-factorial ANCOVA which compared all these effects against one another, and against the corrected null hypothesis model. A priori, we assumed all models to be equally likely. We applied default Jeffreys-Zellner-Siow priors, with the seed set to 84293. Please see Table 2 for a summary of the statistical measures we will be reporting. All Bayesian analyses were conducted in *Jeffreys’s Amazing Statistics Program* (JASP, 0.14.3). JASP was set to report the corrected null model on top, and to compare all other models against it using BF10. Bayes factors do not require thresholding akin to $P < 0.05$ to determine statistical significance: instead they fall on a continuum ranging from support for the null hypothesis via no support for either hypothesis to support for the alternative hypothesis.

Additionally, we can add qualitative descriptors by stating that BF10 > 100 constitutes ‘extreme evidence’ for H1, BF10 > 30 constitutes ‘very strong’ evidence for H1, BF10 > 10 constitutes ‘strong’ evidence for H1 and BF10 > 3 constitutes ‘moderate’ support for H1.

### Data availability

The original, individual MRI files are not available due to participant confidentiality and privacy concerns. The brainAgeR toolbox is freely available at [https://github.com/james-colebrainAgeR](https://github.com/james-colebrainAgeR). The PAD score information was
Table 2 Statistical Measures in Bayesian Probability

| Notation/Abbreviation | Full Name | Interpretation |
|-----------------------|-----------|----------------|
| Prior                 | Prior distribution | Distribution of the effect size, as assumed prior to data collection/analysis |
| Posterior             | Posterior distribution | Actual distribution of the effect size after the data at hand have been analysed |
| $R(M)$                | Prior model probability | Probability of this particular statistical model being supported by the data at hand, as assumed prior to data collection/analysis |
| $R(M)_{data}$         | Posterior model probability | Posterior probability of this particular model being supported by the data at hand, after they have been analysed |
| BF                    | Bayes factor | The strength of evidence in favour of a given statistical model, relative to another statistical model (see below) |
| $BF_{10}$             | Bayes factor 0/1 | The strength of evidence in favour of Model 0, relative to Model 1 |
| $BF_{01}$             | Bayes factor 1/0 | The strength of evidence in favour of Model 1, relative to Model 0 |
| $BF_{10} > 100$       | ‘Extreme evidence’ favouring Model 1, relative to Model 0 |
| $BF_{10} > 30$        | ‘Very strong evidence’ favouring Model 1, relative to Model 0 |
| $BF_{10} > 10$        | ‘Strong evidence’ favouring Model 1, relative to Model 0 |
| $BF_{10} > 3$         | ‘Moderate evidence’ favouring Model 1, relative to Model 0 |
| $BF_{10} = 1$         | Model 1 and Model 0 are equally supported by the evidence |
| $BF_{10} < 0.33$      | ‘Moderate evidence’ against Model 1, relative to Model 0 (equivalent to $BF_{01} > 3$) |
| $BF_{10} < 0.10$      | ‘Strong evidence’ against Model 1, relative to Model 0 (equivalent to $BF_{01} > 10$) |
| $BF_{10} < 0.03$      | ‘Very strong evidence’ against Model 1, relative to Model 0 (equivalent to $BF_{01} > 30$) |
| $BF_{10} < 0.01$      | ‘Extreme evidence’ against Model 1, relative to Model 0 (equivalent to $BF_{01} > 100$) |
| Error%                | Stability of the BF | The range of the BF over the chosen Markov chain Monte Carlo iterations, e.g. $BF_{10} = 10$ with error% = 20 means that the $BF_{10}$ ranged from 8 to 12 |
| 95% CI                | Credible interval | With 95% certainty, the true effect size lies within these bounds |

Predicted brain age was only increased in cognitively/behaviourally impaired patients with ALS

Prior to analysing possible disease effects, we checked that the pretrained brain-age model included in the brainAgeR software was appropriate for our dataset, as it was established on 3377 independent healthy people. For this, we evaluated the PAD (i.e. calculated brain age—chronologic age at time point of MRI) in our HC cohort. As shown in Fig. 1A, the control cohort revealed a (perfectly) matching PAD score of $-1.30 \pm 6.00$ years (mean ± SD) with homogeneous variability across the age range.

We first investigated whether PAD differed between HC and patients with ALS in general. Surprisingly, patients with ALS in general did not show increased brain age (Fig. 1A). The hypothesis that PAD score of $-1.06 \pm 7.14$ years (mean ± SD) in patients with ALS did not differ from HCs was six times more plausible than the hypothesis that fluctuations of PAD score were increased in cognitively/behaviourally impaired patients with ALS through the severity of impairment. The main effect of Strong profile was 524 times more plausible than the hypothesis that fluctuations of PAD score were driven by age, sex or recruitment location (Table 3, $BF_{10} = 524.74$, considered ‘extreme evidence’). The ALSci and ALS-FTD patients showed significantly greater brain age.

Results

Patient cohort

The patients’ onset types included bulbar ($n = 41$), spinal ($n = 53$) or uncertain ($n = 18$). Phenotypically, the patients presented with classical ($n = 68$), upper motor neuron dominant ($n = 12$), flail arm ($n = 6$), flail leg ($n = 6$) or other ($n = 18$) ALS. According to the El Escorial criteria, 40/29/21 patients underwent genetic testing, with four cases with mutations in $\text{SOD1}$, alongside 29 ALSci, 12 ALSbi, 5 ALSchi and $n = 8$ ALS-FTD patients. All patients underwent genetic testing, with four cases with mutations in $\text{C9orf72}$, three cases of $\text{superoxide dismutase 1 (SOD1)}$, one case of $\text{vesicle-associated membrane protein-associated protein B/C (VAPB)}$, one case of a juvenile ALS with $\text{senataxin (SETX)}$ mutation and an uncertain familial link emerging. The remaining patients had sporadic ALS. Demographic and clinical characteristics of the study populations are shown in Table 1. The recruitment flow is shown in Supplementary Fig. 1.

Table 3, BF10

According to the El Escorial criteria, 40/29/21 patients underwent genetic testing, with four cases with mutations in $\text{SOD1}$ or uncertain ($n = 58$), alongside 29 ALSci, 12 ALSbi, 5 ALSchi and $n = 8$ ALS-FTD patients. All patients underwent genetic testing, with four cases with mutations in $\text{C9orf72}$, three cases of $\text{superoxide dismutase 1 (SOD1)}$, one case of $\text{vesicle-associated membrane protein-associated protein B/C (VAPB)}$, one case of a juvenile ALS with $\text{senataxin (SETX)}$ mutation and an uncertain familial link emerging. The remaining patients had sporadic ALS. Demographic and clinical characteristics of the study populations are shown in Table 1. The recruitment flow is shown in Supplementary Fig. 1.
compared with ALScn patients and HC (Fig. 1B). ALS-FTD patients’ brains exhibited strong to extreme evidence for greater added ageing (8.58 ± 9.18 years; mean ± SD), compared with the HC (BF$_{10} = 221.80$, ‘extreme evidence’), ALScn (BF$_{10} = 12918.68$, ‘extreme evidence’) and ALSbi groups (BF$_{10} = 10.03$, strong evidence). ALSci patients’ brains had second highest PAD (2.27 ± 6.40 years, mean ± SD, Fig. 1B); evidence was modest that this was more pronounced than in the HC’s brains (BF$_{10} = 4.55$), and extremely strong evidence compared with ALScn patients’ brains (BF$_{10} = 2735.58$). The effects in our data were not strong enough to provide sufficient evidence for or against differences between the ALScbi and ALSbi groups, possibly because these groups exhibited heterogenous effects on PAD as reflected by their large credible intervals including zero (see Supplementary materials). Unexpectedly, we found modest evidence that ALScn patients’ brain age was moderately lower than those of the HC group (−4.33 ± 5.79 years, mean ± SD, BF$_{10} = 7.71$). In our data, the hypothesis that ALScn patients have younger appearing brains was seven times more likely than the absence of any differences. Predicted brain age correlated well with chronologic brain age in HCs, in ALScn and ALS-impaired (ci, bi, cbi and FTD; Pearson’s rho between 0.66 and 0.99, see Fig. 1C).

The above provides compelling and novel evidence that brain age increases at different speeds across different clinical subgroups of ALS, and that brain age is associated with survival time. We re-ran the above analyses while excluding the 22 patients whose ALS did not meet the El Escorial criteria, and those who had genetic variants of the disease. This did not fundamentally affect the above conclusions with one exception: the difference between ALScn and HC prevailed when either uncertain El Escorial types were excluded (BF$_{10} = 7.71$; Supplementary Fig. 2), or when genetic variants were excluded (BF$_{10} = 7.30$; Supplementary Fig. 3). Therefore, we did not exclude those for further analysis,
being most likely more representative for typical clinical settings.

**Predicted brain age was not influenced by motor subtypes but by disease progression rate**

Different motoric phenotypes of ALS—classical ALS, UMN/LMN ALS, flail arm, flail leg, PMA—did not exhibit differences in brain ageing (Fig. 2A): motoric phenotype effect decreased in plausibility from the prior model probability $P(M) = 2\%$ to a posterior model probability $P(M|data) < 0.0001\%$ a posteriori. Consequently, the Bayesian analysis of effects demonstrated that models excluding the motoric phenotype variable were four times better than those including phenotype ($BF_{excl} = 4.60$), and models excluding disease onset site were five times better than those including disease onset site ($BF_{excl} = 4.94$). The plausibility of onset site’s effect on brain ageing also decreased from 1.6\% to below 0.0001\% (Supplementary Fig. 4A). In summary, clinicomotoric aspects of ALS did not affect brain ageing. Our data further supported the absence of correlations between increased brain ageing and age at disease onset (Pearson’s $r = 0.03$ with a 95\% credible interval ranging from $-0.155$ to 0.212, $BF_{01} = 8.06$), and disease duration until the time point of MRI investigation (Pearson’s $r = -0.127$ with a 95\% credible interval between $-0.301$ and 0.060, $BF_{01} = 3.54$; Supplementary Fig. 5).

We next asked whether upper motor neuron involvement was the key driver of increased PAD score, so we grouped the PMA and LMN groups (including flail-arm and flail-leg syndrome) and compared them with all others. However, the evidence regarding a potential effect of upper motor neuron involvement was inconclusive: our data decreased the effect’s plausibility by a factor of 104 but at $BF_{10} = 0.77$, no hypothesis was preferable to the other (Supplementary Fig. 4B).

Several clinical studies reported differential therapeutic effects in rapid versus slow-progressing patients with ALS suggesting that rapid disease progression might represent a distinct disease type. Thus, we directionally hypothesized that fast progressors—dichotomized by a monthly decline of ALS functional rating scale revised (ALSFRS-R) $\geq 0.5$—would exhibit increased brain age. There was moderate evidence favouring the main effect (Table 3, $BF_{10} = 5.52$) which we followed up with an informed Bayesian ANOVA to specifically test our directional hypothesis. It was 262.61 times more plausible than the effects of
chronologic age, sex and recruitment location alone. As shown in Fig. 2B, slow progressors’ brains were younger than their chronologic age (−4.25 ± 6.75 years). Of note, lower PAD in slow progressors was independent of their chronologic age (M = 1.6% to −0.884, BF10 = 7.31) when it came to explaining PAD scores. This informs us that Strong profile was the more plausible predictor for brain ageing but both were independently relevant (Table 3).

PAD correlated with survival time

We next investigated predictive power of brain ageing on disease duration/survival. Survival data were available for 83 patients. Firstly, the correlation between increased PAD and shorter total disease duration was 250 times more plausible than the absence of any correlation (Kendall’s tau = −0.291 with a credible interval from −0.423 to −0.139, BF10 = 250.206; Fig. 3A). The total disease duration was estimated based on patients’ memory of their own disease onset. In addition, we correlated the disease duration from time point of MRI to death and PAD. The correlation between older appearing brain and shorter survival was 97 times more plausible than the absence of any correlation (Kendall’s tau = −0.272 with a 95% credible interval of −0.405 to −0.120, BF10 = 96.94; Fig. 3B).

What is the focal representation of increased brain age in ALS?

We were wondering to what degree PAD score correlated with motor cortex atrophy. In addition, we tested with which brain volumes PAD score was associated in controls. Correlation of PAD and whole-brain grey-matter maps showed significantly different patterns between healthy elderly people and patients with ALS. While in healthy elderly people, the focal representation of increased PAD score was mainly seen in midcingulate cortex, rolandic operculum and postcentral gyrus (Voxels >1000; t-score >4.5; uncorrected P < 0.001; Fig. 4A), patients with ALS showed remarkable focal atrophy in frontotemporal and motor cortex as well as in the thalamus (Fig. 4B). Thus, PAD was associated with motor cortex atrophy in both, HCs and patients with ALS. This also means that motor cortex atrophy was not correlated with PAD score exclusively in patients with ALS (Supplementary Fig. 6A and B). Frontobasal structures distinguished the PAD-VBM correlations between ALScn compared with ALSi (ci, bi, cbi and FTD; Supplementary Fig. 6C) or HC compared with ALSi (Supplementary Fig. 6D).

What are possible resilience factors?

We next investigated which focal brain map patterns contributed best to the younger brain age in slowly progressive patients with ALS. We compared voxel-wide grey-matter

Cognitive/behavioural impairment and disease progression were independent but additive predictors of PAD

A posteriori, the most plausible effects in our data were the co-occurring but independent main effects of Strong profile and progressor type: they increased in probability from \( P(M) = 1.6\% \) to \( P(M|data) = 24\% \) and were nearly 5000 more likely than the sole influences of chronologic age, sex and recruitment location (\( P(M) = 0.016, P(M|data) = 0.240, BF_{10} = 4803.70, \text{ error}\% = 3.57 \)). This ANCOVA was also able to discriminate between suitable and unsuitable predictors. Models containing Strong profile were 579 times better than those without this predictor (\( P(incl) = 0.500, P(incl|data) = 0.998, BF_{incl} = 579.20 \)), and models containing progressor type were seven times better than models without it (\( P(incl) = 0.500, P(incl|data) = 0.884, BF_{incl} = 7.31 \)) when it came to explaining PAD scores. This informs us that Strong profile was the more plausible predictor for brain ageing but both were independently relevant (Table 3).
volumes between ALS fast versus slow progressors and identified significant regional atrophy mainly in the operculum and temporal lobe (Voxels $\sim 1000$, $t$-value $>4.0$; Fig. 4C) in fast compared with slow progressors.

We finally studied the surprisingly younger brain age in ALScn patients and compared voxel-wide grey-matter volumes between ALScn cases and controls. We identified few and only very small significant focal atrophy patterns (Voxels $<50$, $t$-value $>3.5$) in ALScn patients compared with HCs. Of note, however, we detected relative increase of grey-matter volume in ALScn patients compared with controls in left Crus II and left Lobule VIIa (Voxels $>250$, $t$-values $>3.0$; Fig. 4D).

**Discussion**

We used volumetric MRI with data-driven machine-learning algorithms to estimate individuals’ brain age in patients with ALS and age-matched controls. We had hypothesized that PAD would be increased in motor impairment-only ALS cases and that this effect would even be more pronounced in the presence of additional cognitive and behaviour impairment. PAD was a very stable parameter of the individual, neither affected by age of onset, motor subtypes, disease onset type or disease duration until time point of investigation. Against our a priori hypothesis, we found strong evidence that predicted brain age was not increased in ALS *per se*; however, higher PAD was observed in patients with ALS who were additionally cognitively and/or behaviourally impaired. Surprisingly, predicted brain age was lower in ALScn patients and the subgroup of slowly progressive patients with ALS when compared with HCs. While a significant number of studies reported increased PAD in disease conditions such as Alzheimer’s disease, multiple sclerosis, epilepsy or schizophrenia, none have reported reduced/younger brain ages in a disease condition.

To better understand the unexpected results of younger brain age in ALScn compared with controls, we went on to investigate correlations between PAD and grey-matter volume in a VBM analysis. Our initial hypothesis was that the correlate for PAD score variance in ALS was motor cortex atrophy. Indeed, PAD correlated with motor cortex grey matter, but also with large areas outside of motor cortex.
Table 3 Summary of the Model Comparisons based on the Bayesian ANCOVA

| Model Name                                      | P(M) | P(M|data) | BF_{10} | Error% |
|------------------------------------------------|------|---------|---------|--------|
| Null model (incl. sex, age, recruitment location) | 0.02 | 5.02e−5 | 1.00    |        |
| Strong profile + progressor type                | 0.02 | 0.24    | 4803.70 | 1.970  |
| Strong profile                                  | 0.02 | 0.03    | 524.74  | 3.30   |
| Progressor type                                 | 0.02 | 2.56e−5 | 5.52    | 3.43   |
| Disease duration until examination              | 0.02 | 8.55e−5 | 1.70    | 3.21   |
| Phenotype                                       | 0.02 | 2.16e−5 | 0.43    | 3.15   |
| Age at onset                                    | 0.02 | 1.18e−3 | 0.37    | 3.49   |
| Onset type                                      | 0.02 | 3.87e−4 | 0.12    | 3.32   |
| LMN versus UMN                                  | 0.02 | 2.75e−3 | 0.77    | 3.42   |

BF_{10}, Bayes factor in favour of the model compared with the null model; error%, numerical stability of the BF_{10} over 10,000 MCMC iterations; LMN, lower motor neuron dominant; P(M), prior probability of this model; P(M|data), posterior probability of this model after data analysis; UMN, upper motor neuron dominant.

(Fig. 4 and Supplementary Fig. 6). PAD score was associated with frontotemporal lobe atrophy, consistent with pattern of brain atrophy found in ALS cases with cognitive and/or behavioural impairment. Furthermore, focal temporal lobe atrophy pattern was the morphologic correlate of increased PAD score in fast versus slow progressors (Fig. 4C). Similar atrophy patterns were recently reported in other VBM studies. Together these data inform us that the used machine-learning algorithm was sensitive enough to detect changes typically found in patients with ALS and distinct ALS populations.

One of the key findings was the surprisingly lower brain age of ALScn patients compared with HCs and the increased relative brain volume in cerebellar structures. Of note, Qiu and colleagues reported increased grey-matter volume in cerebellar subregions in a VBM study. Similarly, Zhou and colleagues reported an increased brain functional network connectivity in the cerebellum of patients with ALS. Since both studies excluded patients with an FTD diagnosis and cognitive impairment (MoCA <26), these patients very much resembled our ALScn group. The cerebellum contributes to executive functions such as planning, verbal fluency, abstract reasoning and working memory. All of these functions are typically impaired in ALS patients. Thus, cerebellar compensation may be specifically important in cognitively unimpaired patients with ALS and thus could be considered as resilience factor against executive dysfunction associated with shortened survival.

Consequently, the question arises as to how this translates, e.g. to C90RF72-ALS patients, the most common monogenetic form of ALS. In C90RF72 patients, most abundant dipeptide repeat–associated neuropathology is found in the cerebellum. It is remarkable though that C90RF72 patients do much more often suffer from cognitive/behavioural impairment and shorter survival than sporadic patients with ALS. In agreement with these data, our findings suggest a cerebellar resilience factor against cognitive/behavioural impairment associated with longer survival in patients with ALS which needs further testing in independent cohorts.

We cannot yet generalize whether motor system neurodegeneration without cognitive affection does not lead to accelerated brain ageing also in other motor neurodegenerative diseases such as Parkinson’s disease, or whether this is a specific finding for ALS. Only two studies on Parkinson’s disease have been published so far, both reporting ‘surprisingly’ small increases in PAD, especially when compared with Alzheimer’s disease. Of note, neither study distinguished systematically between demented, cognitively impaired and non-demented Parkinson’s disease patients. However, they showed a negative correlation between cognitive performance (measured by MoCA) and PAD. Thus, future studies are needed, separating Parkinson’s disease patients with and without (mild) cognitive impairment to address this question.

Limitations of the study are the small sample sizes of ALS subgroups, specifically in the ALSbi, –cbi and –FTD subgroups, which is also true for the motoric phenotypes. This did not allow us to analyse all suspected confounding factors such as diets, environmental pollutants, trauma, drug use, etc. Thus, there is considerable heterogeneity in the whole cohort which might explain some of the variances, e.g. in disease duration. However, this distribution reflects the population incidence of motor subtypes and cognitive/behavioural impairment, as ALS presents very heterogeneously. Importantly, small sample sizes serve to detect large or very large effects, as reported here. However, this limitation does not apply to the overall results of a negative PAD in ALScn and positive PAD only in case of additional cognitive and/or behavioural impairment. Nevertheless, larger follow-up studies are warranted to further determine PAD and the underlying processes in the different forms of ALS. Furthermore, the brain-age analysis pipeline yields a single value and its ease of use might make it well suited in routine clinical care. However, it is conceptualized on the whole brain and distinct neuroanatomical information are not available. Consequently, it might not be sensitive enough for every disease entity depending on the spatial patterns of brain atrophy.

Therefore, we performed extensive correlations using VBM analysis. By doing so, we can conclude that we showed here the value of brain-age algorithms in the motor neurodegenerative disease ALS. In addition, we report unexpected findings of younger brain age in patients with ALS without cognitive/behavioural impairments (‘cognitive normal’) not only if compared with ALSi (=ci, bi, cbi or FTD) patients but even if compared with HCs with possible cerebellar resilience factors against cognitive/behavioural impairment in ALS.

Acknowledgements

The authors acknowledge all patients and healthy controls for their participation in the intersite project. J.M. is funded...
by the federal state of Saxony-Anhalt and the European Regional Development Fund (ERDF) in the Center for Behavioral Brain Sciences (CBBS, ZS/2016/04/78113).

**Funding**

This work was supported in part by the NOMIS foundation, the Boris Canessa ALS foundation and the Hermann und Lilly Schilling-Stiftung für medizinische Forschung im Stifterverband. None of those had any role in the design and execution of this study, nor in the subsequent analyses and interpretation of the data, nor in the decision to publish the results. We were not paid to write this article by a pharmaceutical company or other agency.

**Competing interests**

The authors report no competing interests.

**Supplementary material**

Supplementary material is available at *Brain Communications* online.

**References**

1. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol* 2013; 74(1):20-38.

2. Prudlo J, Konig J, Schuster C, et al. TDP-43 pathology and cognition in ALS: A prospective clinicopathologic correlation study. *Neurology* 2016;87(10):1019-1023.

3. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. *J Neurol Neurosurg Psychiatry* 1970; 33(3):338-337.

4. Gorges M, Vercruysse P, Muller HP, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol* 2008;67(12):1022-1030.

5. Bensimon G, Lacomblez L, Meinninger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. *N Engl J Med* 1994;330(9):585-591.

6. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. *Neurology* 2011;76(14):1263-1269.

7. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: A prospective study. *Neurology* 2005;64(7):1222-1226.

8. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis—Frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18(3-4):153-174.

9. Rasovskyy K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134(Pt 9):2456-2477.

10. Collaborators GBDMND. Global, regional, and national burden of motor neuron diseases 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2018;17(12):1083-1097.

11. Raz N, Rodrigue KM. Differential aging of the brain: Patterns, cognitive correlates and modifiers. *Neurosci Biobehav Rev* 2006;30(6):730-748.

12. Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span. *Nat Neurosci* 2003;6(3):309-315.

13. Franke K, Gaser C. Ten years of BrainAGE as a neuroimaging biomarker of brain aging: What insights have we gained? *Front Neurol* 2019;10:789.

14. Cole JH, Raffel J, Friede T, et al. Longitudinal assessment of multiple sclerosis with the brain-age paradigm. *Ann Neurol* 2020;88(1):93-105.

15. Cole JH, Marioni RE, Harris SE, Deary IJ. Brain age and other bodily ‘ages’: Implications for neuropsychiatry. *Mol Psychiatry* 2019; 24(2):266-281.

16. Wrigglesworth J, Ward P, Harding IH, et al. Factors associated with brain ageing—A systematic review. *BMC Neurol* 2021;21(1):312.

17. de Lange AG, Anaturk M, Suri S, et al. Multimodal brain-age prediction and cardiovascular risk: The Whitehall II MRI sub-study. *Neuroimage* 2020;222:117292.

18. Cole JH, Ritchie SJ, Bastin ME, et al. Brain age predicts mortality. *Mol Psychiatry* 2018;23(5):1383-1392.

19. Schuster C, Kasper E, Dybø M, et al. Cortical thinning and its relation to cognition in amyotrophic lateral sclerosis. *Neurobiol Aging* 2014;35(1):240-246.

20. Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. *Nat Rev Neurol* 2014;10(11):661-670.

21. Ashburner J. A fast diffeomorphic image registration algorithm. *NeuroImage* 2007;38(1):95-113.

22. Temp AGM, Naumann M, Hermann A, Glass H. Applied Bayesian approaches for research in motor neuron disease. *Front Neurol* 2022;13:796777.

23. Albuquerque M, Andrade H, Silva C, Nucci A, Franca J, Marcondes. Voxel-based morphometry (VBM) study in ALS (amyotrophic lateral sclerosis): Temporal cortical damage as a prognostic marker (P4.097). *Neurology* 2014;82(10 Supplement):P4.097.

24. Qu T, Zhang Y, Tang X, et al. Precentral degeneration and cerebellar compensation in amyotrophic lateral sclerosis: A multimodal MRI analysis. *Hum Brain Mapp* 2019;40(12):3464-3474.

25. Zhou C, Hu X, Hu J, et al. Altered brain network in amyotrophic lateral sclerosis: A resting graph theory-based network study at voxel-wise level. *Front Neurosci* 2016;10:204.

26. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. *Brain* 1998;121(4):561-579.

27. Mackenzie IR, Frick P, Grasser FA, et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. *Acta Neuropathol* 2015;130(6):845-861.

28. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study. *Lancet Neurol* 2012;11(3):232-240.

29. Eickhoff SR, Hoffstaedter F, Caspers J, et al. Advanced brain ageing in Parkinson’s disease is related to disease duration and individual impairment. *Brain Commun* 2021;3(3):fcab191.

30. Beheshti I, Mishra S, Sone D, Khanna P, Matsuda H. T1-weighted MRI-driven brain age estimation in Alzheimer’s disease and Parkinson’s disease. *Aging Dis* 2020;11(3):618-628.